Romiplostim: A novel c-Mpl/CD110 receptor ligand for the management of idiopathic thrombocytopenic purpura

H. Patel, N. Patel, A. Vyas, M. Patel, S. Pandey

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Idiopathic Thrombocytopenic Purpura (ITP) is an autoimmune disease characterised predominantly by an antibody mediated destruction of platelets. Few treatment options are available for ITP like corticosteroids, IV immunoglobulins, splenectomy, rituximab, danazole and cyclophosphamide. All these treatment options work by reducing the destruction of platelets by antibody. However recent evidence suggests that production of platelet is reduced in 75% of thrombocytopenic patient with ITP. Romiplostim is a novel thrombopoetin receptor agonist approved by USFDA in August 2008 that increases the platelet count in ITP patients unresponsive to corticosteroids, immunoglobulins or splenectomy. Romiplostim is not currently available in India. The addition of Romiplostim in the treatment options for ITP will surely improve the outcomes in ITP patients.
Original languageEnglish
Pages (from-to)1690-1696
Number of pages7
JournalJournal of Clinical and Diagnostic Research
Volume3
Issue number4
Publication statusPublished - 2009

Fingerprint Dive into the research topics of 'Romiplostim: A novel c-Mpl/CD110 receptor ligand for the management of idiopathic thrombocytopenic purpura'. Together they form a unique fingerprint.

  • Cite this